Trichome Capital is an independent advisory firm specialized in providing corporate finance, strategic consulting and investment management services to the regulated cannabis industry and parallel sectors including agribusiness, food and beverage, as well as healthcare.
We operate primarily in the lower middle market and provide tailored advice to investors, companies, shareholders and management teams on a variety of issues from mergers & acquisitions, divestments, capital raises, new business ventures (start-ups), etc.
The independence of our firm ensures we’re totally aligned with our clients’ interests from start to finish of a project, and allows us to create long term relationships built on trust, integrity and absolute transparency.
Transform your business
We help companies define and implement strategic plans to successfully bring the future into focus.
Accelerate growth via acquisitions
We provide clients with expert advice throughout the entire acquisition process.
Maximize shareholder value
Our tailored approach and complete dedication helps guide business owners to a successful sale.
Find the best investor
We have the contacts and skills required to find the right partner and access funding.
CannabisGreat experience in an emerging market
Focused on helping companies across the entire cannabis value chain
HealthcareGlobal advice for a global industry
Bringing diverse and deep experience to every healthcare engagement
AgribusinessStrong roots in a fundamental sector
Extensive knowledge of the changes occurring in the global agriculture industry
Food and BeverageSound experience across a broad sector
Our “appetite” for this industry provides us with the know-how and contacts to successfully navigate this market
Nicholas Balk – Managing Director
Nicholas is a seasoned professional and entrepreneur with c. 15 years of international finance, consulting and investment experience. He has worked and advised on a multitude of transactions in a variety of sectors and countries however the latter half of his career has been focused primarily on European based projects in the healthcare and agro-food sectors.
Nicholas began his finance career in the Corporate Banking team at HSBC in Australia. He later took a position at Bank of Tokyo Mitsubishi in London in their European Corporate Research division, before moving to a variety of M&A roles at ONEtoONE Corporate Finance and CW Downer & Co. (now Alantra) in Spain. Before founding Trichome Capital, he held the position of M&A Director at Banca March, Spain’s leading private bank.
Nicholas holds a Master of Business from Queensland University of Technology (Australia) and Bachelor degrees in Commerce and International Business from Griffith University (Australia). He also boasts a graduate certificate in cannabis from Oaksterdam University, California and a diploma in Export Management from the Australian Institute of Export. He is fluent in English and Spanish.
Daniel Krupp – VP of Strategy & New Ventures
As a veteran operator in the Fast Moving Consumer Goods space, Daniel brings over a decade of multi-market experience overseeing commercial strategy for some of the world’s most iconic consumer brands, including Coca-Cola, Minute Maid and Monster Energy. Daniel is a subject matter specialist in sales optimization, brand development and route-to-market.
After completing his studies in Sydney, Australia, Daniel embarked on a professional journey that saw him take on senior commercial leadership roles, while working alongside major global retailers, in a diverse mix of mature and emerging markets, including Indonesia, Singapore, Japan, United States, and Continental Europe.
Daniel leads Trichome Capital’s portfolio strategy, with responsibility that includes originating and identifying areas for long-term growth through new venture development and direct investment.
Daniel holds a Bachelor of Commerce degree from Macquarie University and is a certified Chartered Accountant. He has also recently completed his Executive MBA at HEC Paris, a leading business school, ranked 3rd globally by the Financial Times in 2021.